The Weight of Perception: Fatphobia and the GLP-1 Revelation

Weight stigma—often referred to as fatphobia or weight bias—pervades many aspects of life, from healthcare and employment to everyday social interactions. This bias assumes that larger bodies are less desirable, less disciplined, or even less worthy. Meanwhile, a new class of medications known as GLP-1 agonists (including brand names like Ozempic and Wegovy) has made significant weight loss more attainable for many. These drugs, originally developed to treat diabetes, have been repurposed as potent weight-loss aids, leading to dramatic transformations in patients’ bodies​The “GLP-1 revelation” refers to how these rapid weight changes have exposed the extent of fatphobia ingrained in U.S. culture. When individuals shed pounds quickly via weekly injections of semaglutide (the active ingredient in Ozempic)​, they often find that society treats them very differently—revealing biases that were always there. This podcast delves into personal stories from Americans who have experienced this shift, examines psychological impacts of fatphobia, and presents data on the social and economic disparities it causes in the U.S. It also contrasts treatment people get before and after GLP-1-induced weight loss, illustrating what these changes say about American culture’s deep-seated biases.